Payment overview · 2025
General Payments
$647,595.43
478 reported records · 24 companies
Healthcare provider profile · identity verified
Maeve E O'Connor, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CHARLOTTE, NC · NPI 1114956752
Verified facts
What the public records show
CMS Open Payments records show Maeve E O'Connor, MD received $647,595.43 in general payments during 2025 across 478 reported records.
GENZYME CORPORATION accounted for 26.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Hizentra, Xembify.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Symbicort by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Hizentra by this doctor in 2024.
Grifols Shared Services North America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xembify as an associated drug or biological on 95 records involving 62 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xembify by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xembify as an associated drug or biological on 5209 records involving 2197 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Xembify by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAKHZYRO as an associated drug or biological on 3355 records involving 1604 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Takhzyro by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $172,494.20 | 26.6% | 103 | 2025 |
| Consortium of Independent Immunology Clinics, LLC | Unresolved — no canonical attribution shown | $163,847.54 | 25.3% | 1 | 2025 |
| ARS Pharmaceuticals Operations, Inc. | Unresolved — no canonical attribution shown | $71,103.89 | 11.0% | 52 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $65,597.55 | 10.1% | 77 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $45,256.28 | 7.0% | 52 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $26,376.35 | 4.1% | 37 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $25,226.74 | 3.9% | 29 | 2025 |
| Blueprint Medicines Corporation | Unresolved — no canonical attribution shown | $17,283.76 | 2.7% | 13 | 2025 |
| ADMA BioManufacturing LLC | Unresolved — no canonical attribution shown | $16,771.46 | 2.6% | 20 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13,957.56 | 2.2% | 24 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $11,700.78 | 1.8% | 31 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $8,540.89 | 1.3% | 13 | 2025 |
| Regeneron Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3,084.00 | 0.5% | 1 | 2025 |
| Pharming Healthcare, Inc. | Unresolved — no canonical attribution shown | $2,453.50 | 0.4% | 6 | 2025 |
| AQUESTIVE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $2,275.00 | 0.3% | 1 | 2025 |
| SANOFI US SERVICES INC. | Unresolved — no canonical attribution shown | $785.00 | 0.1% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $200.55 | 0.0% | 7 | 2025 |
| GC Biopharma USA, Inc. | Unresolved — no canonical attribution shown | $189.75 | 0.0% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $181.77 | 0.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $95.00 | 0.0% | 1 | 2025 |
| Jubilant HollisterStier LLC | Unresolved — no canonical attribution shown | $59.85 | 0.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.82 | 0.0% | 1 | 2025 |
| Grifols Shared Services North America, Inc. | Unresolved — no canonical attribution shown | $40.42 | 0.0% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $32.77 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $280,294.90 | 81 |
| Consulting Fee | $255,827.81 | 28 |
| Travel and Lodging | $71,966.45 | 146 |
| Honoraria | $27,691.00 | 8 |
| Food and Beverage | $11,773.06 | 212 |
| Education | $25.00 | 1 |
| Gift | $17.21 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc., Regeneron Pharmaceuticals, Inc. | $130,841.87 | 112 | 2025 |
Source payment records
|
|||||
| NEFFY Normalized: neffy |
Drug | ARS Pharmaceuticals Operations, Inc. | $71,103.89 | 52 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $64,583.84 | 66 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $29,760.84 | 31 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological, Drug | Blueprint Medicines Corporation, GENZYME CORPORATION, SANOFI US SERVICES INC. | $26,258.76 | 13 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $24,924.64 | 23 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15,300.84 | 16 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $13,887.80 | 20 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $8,540.89 | 13 | 2025 |
Source payment records
|
|||||
| Rhapsido Normalized: rhapsido |
Drug | Novartis Pharmaceuticals Corporation | $5,080.78 | 15 | 2025 |
Source payment records
|
|||||
| RUCONEST Normalized: ruconest |
Biological | Pharming Healthcare, Inc. | $2,453.50 | 6 | 2025 |
Source payment records
|
|||||
| LIBERVANT Normalized: libervant |
Drug | AQUESTIVE THERAPEUTICS, INC. | $2,275.00 | 1 | 2025 |
Source payment records
|
|||||
| ALYGLO Normalized: alyglo |
Drug | GC Biopharma USA, Inc. | $189.75 | 2 | 2025 |
Source payment records
|
|||||
| Xolair Normalized: xolair |
Biological | Genentech USA, Inc. | $181.77 | 3 | 2025 |
Source payment records
|
|||||
| Haegarda Normalized: haegarda |
Biological | CSL Behring | $175.90 | 4 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $150.20 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $95.00 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $88.61 | 3 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols Shared Services North America, Inc., Grifols USA, LLC | $73.19 | 2 | 2025 |
Source payment records
|
|||||
| ACTIMMUNE Normalized: actimmune |
Biological | Amgen Inc. | $40.82 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $9.49 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $2.67 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Hizentra hizentra |
2025 | Hizentra | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Xembify xembify |
2025 | Xembify | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Grifols Shared Services North America, Inc. Exact reporting entity; no affiliate inference |
2025 | Xembify open payments reported associated product |
CMS Open Payments — General Payments 95 supporting records · 62 recipient NPIs · example record 1249529400 |
Xembify · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Xembify open payments reported associated product |
CMS Open Payments — General Payments 5209 supporting records · 2197 recipient NPIs · example record 1249529389 |
Xembify · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TAKHZYRO open payments reported associated product |
CMS Open Payments — General Payments 3355 supporting records · 1604 recipient NPIs · example record 1223616316 |
Takhzyro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Montelukast Sodium | Montelukast Sodium | 35 | 15 |
| Famotidine | Famotidine | 29 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Xembify | Immune Globulin,gamma(Igg)klhw | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 13 | suppressed |
| Takhzyro | Lanadelumab-Flyo | 13 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $647,595.43 · 478 records | GENZYME CORPORATION | ACTIMMUNE, AIRSUPRA, ALYGLO, AYVAKIT, Andembry, CUVITRU, DAWNZERA, DUPIXENT, EOHILIA, FASENRA, HYQVIA, Haegarda, Hizentra, LIBERVANT, NEFFY, NUCALA, Ohtuvayre, RUCONEST, Rhapsido, TEZSPIRE, Xembify, Xhance, Xolair | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Hizentra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error